Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STIMATE (NEEDS NO REFRIGERATION) vs DESMODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.
Central diabetes insipidus (approved by FDA),Primary nocturnal enuresis (approved by FDA),Hemophilia A with factor VIII deficiency (off-label),von Willebrand disease (type I, some type II and III) (off-label),Nocturia in multiple sclerosis (off-label),Uremic bleeding (off-label)
Central diabetes insipidus,Primary nocturnal enuresis,Hemophilia A with factor VIII levels >5%,von Willebrand disease (type I)
Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.
10 mg orally once daily
Terminal elimination half-life is 2-4 hours (mean 3 hours), which supports a dosing interval of 2-4 hours in clinical use.
Terminal half-life: 8-12 hours; extended in renal impairment (up to 24 hours).
Primarily metabolized by the liver via reduction of the disulfide bridge by glutathione, and to a lesser extent by proteolysis. The metabolite is not active. Excretion: renal (filtration and tubular secretion).
Metabolized primarily by reduction of disulfide bonds; not extensively metabolized by CYP450 enzymes.
Renal excretion of intact drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minimal (<5%).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Plasma protein binding is approximately 50-60%, primarily to albumin and to a lesser extent alpha-1 acid glycoprotein.
95%; primarily binds to albumin and alpha-1-acid glycoprotein.
Volume of distribution is 0.2-0.4 L/kg, indicating moderate distribution into total body water and some tissue binding.
Vd: 0.5-0.7 L/kg; indicates moderate tissue distribution.
Intranasal: 10-20%; Intravenous: 100%; Sublingual: 5-10%; Oral: <1% (extensive first-pass metabolism).
Oral: 85-90% with food; 70-80% fasting.
No dose adjustment required for renal impairment. Insufficient data for GFR-based modifications.
No adjustment required for GFR ≥30 m L/min; contraindicated if GFR <30 m L/min
No specific Child-Pugh based dose adjustments available. Use with caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 5 mg once daily; Child-Pugh C: contraindicated
Intranasal: <50 kg: 1 spray (1.5 mg) into one nostril; ≥50 kg: same as adult. May repeat once after 30-60 minutes.
Not recommended for use in pediatric patients
No specific dose adjustment recommended. Monitor for adverse effects due to potential comorbidities and concomitant medications.
Initiate at 5 mg once daily; monitor renal function closely
WARNING: HYPONATREMIA and SEIZURES. Desmopressin can cause severe hyponatremia, which may be life-threatening if not promptly treated. Seizures have been reported. Risk is increased in patients with fluid or electrolyte imbalances, cystic fibrosis, heart failure, or those on medications that increase hyponatremia risk.
No FDA black box warning.
Hyponatremia and seizures: monitor serum sodium in patients at high risk; avoid excessive fluid intake.,Cardiovascular: caution in patients with coronary artery disease or hypertension, as increased blood pressure or ischemia may occur.,Fluid retention: avoid in patients with conditions predisposing to fluid overload (e.g., heart failure).,Thrombotic events: use cautiously in patients with risk factors for thrombosis (e.g., advanced atherosclerosis, smoking, oral contraceptives).,Renal impairment: dose reduction may be necessary; monitor renal function.,Cystic fibrosis: increased risk of hyponatremia and seizures.,Hypersensitivity: anaphylactic reactions reported; discontinue if allergic reaction occurs.
Risk of hyponatremia and seizures, especially in children and patients on fluid overload,Fluid restriction should be observed,Use with caution in patients with electrolyte imbalance, renal impairment, cystic fibrosis, or coronary artery disease,Avoid in patients with primary polydipsia
Hypersensitivity to desmopressin or any component of the formulation,Moderate to severe renal impairment (creatinine clearance <50 m L/min),Hyponatremia or history of hyponatremia,Primary nocturnal enuresis in patients with polydipsia or excessive fluid intake,Uncontrolled hypertension,Coronary artery disease of any cause,Thrombotic states (e.g., deep vein thrombosis, pulmonary embolism),Patients on medications that increase hyponatremia risk (e.g., SSRIs, NSAIDs, diuretics) unless closely monitored
Hypersensitivity to desmopressin or any component,Moderate to severe renal impairment (Cr Cl <50 m L/min),Hyponatremia or history of hyponatremia,Primary polydipsia,Patients on diuretics or other drugs that increase risk of hyponatremia
Avoid high-sodium foods that may increase thirst and fluid intake. Grapefruit juice may increase desmopressin absorption (monitor for enhanced effect). No other significant food interactions.
Avoid concurrent intake of large volumes of water or hypotonic fluids. Alcohol may reduce antidiuretic effect. Caffeine may increase urine output. Grapefruit juice may enhance absorption of oral formulations.
Desmopressin is a synthetic analog of vasopressin. Available data in pregnant women are insufficient to determine drug-associated risk of major birth defects and miscarriage. In animal studies, no teratogenic effects were observed at doses up to 100 times the human dose. Desmopressin does not cross the placenta in significant amounts due to its large molecular weight and enzymatic degradation. During the first trimester, theoretical risk of hyponatremia and seizures in the fetus if maternal hyponatremia occurs. In the second and third trimesters, increased uterine contractility has been reported in some cases. Overall, desmopressin is considered low risk, but caution is advised.
Desmoda is contraindicated in pregnancy. First trimester: Risk of major congenital malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism. Second/Third trimester: Fetal growth restriction, oligohydramnios, premature closure of ductus arteriosus (if NSAID component).
Desmopressin is excreted into human breast milk in very small amounts. The milk-to-plasma (M/P) ratio is not well established but is estimated to be less than 0.1 based on available data. At therapeutic doses, it is unlikely to affect the nursing infant. However, caution is recommended due to potential for water retention and hyponatremia in the infant. Use only if clearly needed.
Excreted in breast milk. M/P ratio not established. Avoid breastfeeding due to potential for serious adverse reactions (e.g., folate deficiency, kernicterus) in the infant.
No standard dose adjustments for pregnancy are required. However, increased clearance of desmopressin during pregnancy may necessitate dose titration based on clinical response and serum sodium levels. For central diabetes insipidus, doses may need to be increased in the second and third trimesters. Close monitoring is essential.
Contraindicated in pregnancy. No dose adjustment recommended; avoid use. If accidental exposure occurs, discontinue immediately and initiate folate rescue therapy.
Stimate (desmopressin acetate) is a synthetic analog of vasopressin used for diabetes insipidus and hemophilia A/von Willebrand disease. It causes vasoconstriction and platelet aggregation; monitor for hyponatremia, especially in elderly or patients with fluid intake >2 L/day. Avoid in patients with severe renal impairment (e GFR <50 m L/min). For nocturnal enuresis, restrict fluid 1 hour before and 8 hours after dose. Needs no refrigeration, but store at room temperature (15-30°C).
Desmopressin is a synthetic analog of vasopressin used for central diabetes insipidus and nocturnal enuresis. Monitor serum sodium, especially in elderly or patients with fluid/electrolyte imbalance. Avoid in patients with hyponatremia or renal impairment. Tachyphylaxis may occur; dose adjustment may be needed. Intranasal route may be less reliable due to mucosal variability.
Do not refrigerate; store at room temperature.,Limit fluid intake for 8 hours after dosing to prevent water intoxication.,Report headache, nausea, confusion, or rapid weight gain (signs of hyponatremia).,If used for bedwetting, take last dose at bedtime and empty bladder before sleep.,Do not use with alcohol or other vasopressin analogs without doctor approval.
Take exactly as prescribed; do not exceed dose to avoid water intoxication.,Fluid restriction is critical: limit fluid intake for 1-2 hours after dosing, especially at night.,Report symptoms of hyponatremia: headache, nausea, vomiting, confusion, seizures.,For enuresis, take last dose at bedtime; avoid drinking 1 hour before and 8 hours after.,Intranasal formulations: administer alternately in each nostril; clear nasal passages before use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STIMATE (NEEDS NO REFRIGERATION) vs DESMODA, answered by our medical review team.
STIMATE (NEEDS NO REFRIGERATION) is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.. DESMODA is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone, ADH) that acts on V2 receptors in renal collecting ducts, increasing water reabsorption and reducing urine output. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor stimulation on endothelial cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STIMATE (NEEDS NO REFRIGERATION) and DESMODA depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STIMATE (NEEDS NO REFRIGERATION) is: Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.. The standard adult dose of DESMODA is: 10 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STIMATE (NEEDS NO REFRIGERATION) and DESMODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STIMATE (NEEDS NO REFRIGERATION) is classified as Category C. Desmopressin is a synthetic analog of vasopressin. Available data in pregnant women are insufficient to determine drug-associated risk of major birth defects and miscarriage. In an. DESMODA is classified as Category C. Desmoda is contraindicated in pregnancy. First trimester: Risk of major congenital malformations (neural tube defects, cardiovascular anomalies) due to folate antagonism. Second/Th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.